Benue State announces the launch of Lenacapavir, a long-acting injectable medicine designed for HIV prevention, with doses administered twice yearly. Both outlets report that the state government presents the drug as part of efforts to reduce new HIV infections and advance progress toward ending AIDS by 2030. The reports frame the move in the context of Benue’s high HIV burden, noting the state as one of Nigeria’s areas most heavily affected by the epidemic and positioning the long-acting prevention option as a more discreet and practical alternative for people who may prefer less frequent dosing.
While details on rollout procedures, eligibility criteria, and distribution mechanisms are not provided in the excerpts, the sources agree that the launch is an official state-level introduction of Lenacapavir for prevention. The drug is described as an injectable that does not require regular injections throughout the year, instead relying on a schedule that renews protection every six months.
